RxDoctor Payments Data

Crystal Gary, MD

Family Medicine · Blairsville, GANPI 1154405207

Payments from drug & device makers

$227in general payments, 2019–2025

Across 13 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$105
  • Amgen$39
  • Novo Nordisk$23
  • Daiichi Sankyo Inc.$20
  • AstraZeneca$15
  • Amarin Pharma, Inc.$13
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$19787%
  • Education$3013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)5$105
Amgen2$39
Novo Nordisk2$23
Daiichi Sankyo Inc.1$20
AstraZeneca1$15
Amarin Pharma, Inc.1$13
Pfizer1$12

How this compares

$227 in reported general payments places this provider in the 35th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$131,528
Medicare patients
247
Services billed
3,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$90,974
MounjaroTirzepatide51$68,135
JardianceEmpagliflozin60$51,299
TrulicityDulaglutide32$41,347
EliquisApixaban36$32,664
FarxigaDapagliflozin Propanediol19$15,236
MyrbetriqMirabegron11$14,313
VimpatLacosamide12$13,153
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$12,061
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$9,629
Repatha SureclickEvolocumab15$8,278
RestasisCyclosporine11$6,985
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$6,097
Metformin Er GastricMetformin Hcl17$5,188
SynthroidLevothyroxine Sodium28$3,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$23$90,97477 claims
PfizerEliquis$12$32,66436 claims
AstraZenecaFarxiga$15$15,23619 claims
AbbVieRestasis, Synthroid, Armour Thyroid$105$11,07855 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Blairsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →